- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05785468
A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI) (ROSCAPLI)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Raimondo De Cristofaro, MD
- Phone Number: 0630156329
- Email: raimondo.decristofaro@policlinicogemelli.it
Study Locations
-
-
-
Roma, Italy, 00168
- Recruiting
- FPG
-
Contact:
- Raimondo De Cristofaro
- Phone Number: 0630156329
- Email: raimondo.decristofaro@policlinicogemelli.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- The patients included in this study should have received caplacizumab for treatment in the period between Q4-2019 and the end of February 2021 while the end of follow up observation is scheduled for Q1-2021 (to observe at least one month of post treatment follow up).
- The diagnosis should be based on either clinical/laboratory parameters inclusive of measurement of ADAMTS13 level <10%) or the PLASMIC score (platelets, lysis, active cancer, stem cell or solid organ transplant, MCV, INR, and creatinine) with intermediate and high risk (sore>5) already computed or retrospectively calculated as previously detailed [19] for centers that did not measure the ADAMTS13 level.
Exclusion Criteria:
- Patients treated with uncertain aTTP diagnosis according to the above inclusion criteria - Patients manifesting clinical signs like aTTP but characterized by a different pathogenesis (e.g. cancer, sepsis)
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
description and quantification of clinical response in terms of platelet count recovery in patients with aTTP treated t with caplacizumab
Time Frame: 18 months
|
The primary objective in this study is the description of clinical response in terms of platelet count recovery in patients with aTTP treated with caplacizumab , in addition to PEX and immunosuppression in the real-world setting.
|
18 months
|
The primary objective in this study is the quantification of clinical response in terms of platelet count recovery in patients with aTTP treated t with caplacizumab
Time Frame: 18 months
|
The primary objective in this study is the quantification of clinical response in terms of platelet count recovery in patients with aTTP treated with caplacizumab , in addition to PEX and immunosuppression in the real-world setting.
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
evaluation of number of exacerbations,rate of relapse and TTP-related mortality
Time Frame: 18 months
|
Secondary objectives include: a) Number of exacerbations, defined as recurrent thrombocytopenia within 30 days after the end of therapy; |
18 months
|
evaluation of number of exacerbations,rate of relapse and TTP-related mortality
Time Frame: 18 months
|
Secondary objectives include: b) Rate of relapse, defined as a TTP event occurring more than 30 days after the end of daily plasma exchange; |
18 months
|
evaluation of number of exacerbations,rate of relapse and TTP-related mortality
Time Frame: 18 months
|
Secondary objectives include: c) Refractoriness; defined by the lack of a doubling of platelet count after 4 days of treatment and a lactate dehydrogenase level that remained above the upper limit of the normal range |
18 months
|
evaluation of number of exacerbations,rate of relapse and TTP-related mortality
Time Frame: 18 months
|
Secondary objectives include: d) TTP-related mortality |
18 months
|
evaluation of number of exacerbations,rate of relapse and TTP-related mortality
Time Frame: 18 months
|
Secondary objectives include: e) Evaluation of adverse events |
18 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4305
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thrombotic Thrombocytopenic Purpura
-
Insel Gruppe AG, University Hospital BernSwiss National Science Foundation; Mach Gaensslen Foundation; Baxalta Innovations...RecruitingThrombotic Thrombocytopenic Purpura | Congenital Thrombotic Thrombocytopenic Purpura | Familial Thrombotic Thrombocytopenic Purpura | Thrombotic Thrombocytopenic Purpura, Congenital | Upshaw-Schulman SyndromeUnited States, Austria, Czechia, Germany, Japan, Norway, Switzerland
-
ShireTakeda Development Center Americas, Inc.CompletedAcquired Thrombotic Thrombocytopenic Purpura (aTTP)United States, Spain, Canada, United Kingdom, France, Germany, Italy
-
TakedaShire; Takeda Development Center Americas, Inc.RecruitingThrombotic Thrombocytopenic Purpura (TTP)China, United States, France, Japan, Poland, Germany, Austria, Spain, Italy, Switzerland, United Kingdom
-
Turkish Hematology AssociationSanofiRecruitingTTP - Thrombotic Thrombocytopenic PurpuraTurkey
-
University of CologneRecruitingAcquired Thrombotic Thrombocytopenic PurpuraGermany
-
Peking Union Medical College HospitalNot yet recruitingThrombotic Thrombocytopenic Purpura, AcquiredChina
-
Fundación Española de Hematología y HemoterapíaRecruitingAcquired Thrombotic Thrombocytopenic PurpuraSpain, Portugal
-
University of CologneRecruitingAcquired Thrombotic Thrombocytopenic PurpuraGermany
-
TakedaAvailableThrombotic Thrombocytopenic Purpura (TTP)
-
Ablynx, a Sanofi companyCompletedAcquired Thrombotic Thrombocytopenic PurpuraUnited States, Austria, Belgium, France, Germany, Israel, Italy, Spain, Switzerland, United Kingdom, Bulgaria, Romania, Australia
Clinical Trials on Caplacizumab
-
SanofiCompletedImmune-mediated Thrombocytopenic PurpuraFrance
-
University Hospital, RouenNot yet recruitingThrombotic Thrombocytopenic Purpura, Acquired
-
US Thrombotic Microangiopathy AllianceNot yet recruitingImmune Thrombotic ThrombocytopeniaUnited States
-
Ablynx, a Sanofi companyCompletedAcquired Thrombotic Thrombocytopenic PurpuraUnited States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Hungary, Israel, Italy, Netherlands, Spain, Switzerland, Turkey, United Kingdom
-
AblynxCompletedHealthy VolunteersUnited States
-
AblynxCompletedHealthy VolunteersUnited Kingdom
-
Ablynx, a Sanofi companyCompletedAcquired Thrombotic Thrombocytopenic PurpuraUnited States, Austria, Belgium, France, Germany, Israel, Italy, Spain, Switzerland, United Kingdom, Bulgaria, Romania, Australia
-
SanofiCompletedAcquired Thrombotic Thrombocytopenic PurpuraUnited States, Austria, Belgium, Canada, Czechia, France, Hungary, Israel, Italy, Spain, Switzerland, Turkey, United Kingdom
-
SanofiRecruitingThrombotic Thrombocytopenic PurpuraItaly, Belgium, France, Greece, United States, Austria, Canada, Czechia, Germany, Japan, Netherlands, Spain, United Kingdom
-
SanofiCompletedThrombotic Thrombocytopenic PurpuraJapan